Science
Mechanism of Action
Oligopeptide-1 primarily functions by binding to Epidermal Growth Factor Receptors (EGFRs) present on keratinocytes and other skin cells. This interaction initiates an intracellular signaling cascade that stimulates cell division, growth, proliferation, and differentiation of epithelial cells. The peptide actively promotes skin repair, enhancing self-regeneration and stimulating blood vessel formation in damaged areas. It also boosts the production of key extracellular matrix components such as collagen, elastin, and hyaluronic acid, which collectively improve skin firmness, elasticity, and hydration. This mechanism supports barrier function, helps suppress inflammatory responses, reduces the appearance of scars, and minimizes fine lines, while also offering protection against collagen damage.
Research
Clinical Evidence
Medium confidence0.0005%
Key findings
- 01 For Oligopeptide-1 powder, a concentration range of 0.0005% to 0.5% (5 to 5000 ppm) in the final formulation is recommended for significant activity.
- 02 A topical EGF serum applied twice daily over 8 weeks led to a 73% decrease in melasma among subjects, with no reported side effects.
- 03 An EGF cream, used on 20 subjects over six weeks, demonstrated a 33.5% reduction in inflammatory acne lesions on the treated side.
- 04 Clinical evaluations of a serum containing barley bioengineered epidermal growth factor showed statistically significant improvements in fine lines, wrinkles, skin texture, pore size, and various pigment abnormalities within the first month, with continued improvement over a 3-month study period.
- 05 sh-Oligopeptide-1 has demonstrated effectiveness in wound healing for diabetic patients after laser treatment and in managing Senile purpura.
- 06 A critical review suggests that many cosmetic clinical studies on sh-oligopeptide-1 lack scientific basis, as the preclinical bioactivity of this molecule has not been definitively proven. The review states sh-oligopeptide-1 is not a functional EGF and is unauthorized for medical treatments, despite its cosmetic authorization at various concentrations with unknown long-term risks.
Transparency
Dusting Analysis
Given the recommended effective concentration range for Oligopeptide-1 powder starts as low as 0.0005%, and the complex scientific debate regarding its functional efficacy in cosmetic applications, there is a risk of 'dusting.' Formulations containing concentrations below this threshold, or those using forms of the ingredient with unproven cosmetic bioactivity, may be included more for marketing claims than for demonstrable skin benefits.
The Formula
Formulation
Stability
Oligopeptide-1 exhibits high sensitivity to temperature and light, requiring an icy storage environment of -20°C or lower for long-term stability, as it rapidly loses activity above 4°C. Exposure to strong light also accelerates chemical decomposition. Microbial contamination is a significant concern during processing due to enzyme-mediated decomposition. When formulating, the pH should be adjusted to the optimal range of 5.0-8.0 before incorporating the diluted EGF solution. Acidic environments (below pH 5), such as those created by AHAs or BHAs, can destabilize growth factors, reducing their efficacy; it is advised to apply acidic products first and allow absorption before layering products containing Oligopeptide-1. The peptide should be incorporated into cosmetic preparations at temperatures below 40°C during the final manufacturing stage.
Conflicts
- Acidic environments (pH below 5)
- High temperatures (above 4°C for long-term storage, above 40°C during formulation)
- Strong light exposure
- Microbial contamination
Safety
Safety Profile
The Cosmetic Ingredient Review (CIR) Expert Panel concluded that Tripeptide-1, a variant sometimes identified with Oligopeptide-1, is safe at current use practices and concentrations. However, significant discussions surround sh-Oligopeptide-1 (EGF). While considered safe due to its biodegradability and natural presence in the body, caution is advised: as a 'growth factor,' any overexpression or dysregulation has the potential to induce tumorigenesis, given that EGF signaling is prevalent in many tumor cells. Active EGF is considered an unauthorized and potent drug, not a cosmetic ingredient. Topical human recombinant EGF (hr-EGF) is not authorized as a medication outside of clinical trials. Sh-EGF (sh-oligopeptide-1) is authorized as a cosmetic in various concentrations for general use, but its long-term risks remain unknown. The China National Drug Administration (NDA) has stated that sh-Oligopeptide-1 should not be used as a cosmetic raw material due to its large molecular weight and difficulty in absorption through an intact skin barrier, citing potential safety issues if the barrier is compromised. It is mitogenic (stimulates cell proliferation) but not mutagenic. Individuals with psoriasis or those at risk of skin cancer are advised to avoid growth factors.
Your Skin
Skin Compatibility
Our Assessment
Verdict
While studies suggest benefits in skin regeneration, anti-aging, and wound healing at concentrations between 0.0005% and 0.5%, significant concerns exist regarding its scientific validation as a functional cosmetic EGF and potential long-term safety risks due to its growth factor activity, warranting cautious consideration and further independent research.
Related
Similar Ingredients
Finding similar ingredients…